Bengaluru: Everest Organics said on Tuesday it had begun to make active pharmaceutical material (API) for the generic version of the experimental antivirus drug Merck & Co.
Molnupiravir to treat Covid-19 which is light to medium.
Everest organic shares jumped as much as 11.6% after the news in, and finally rose 9.9% at Rs 330 in a weak market.
Mass drug manufacturers join the laboratory on Divi as fire makers for Merck’s experimental mouth medicine.
Merck separately signed a voluntary license agreement with at least eight generic drug makers for Molnupiravir, with the aim of transforming the country to become a manufacturing hub for drugs.
“After the success of the development and commercialization of various covid-19 drugs such as Oseltamivir, Remdesivir …
Everest Organics is on the path of this portfolio expansion,” said Chief Executive Officer Srikakarlapudi Sirisha in a statement.
Merck said on Monday it was looking for authorization of US emergency use for drugs, placing Molnupiravir on track to become the first oral antivirus drug for Covid-19.
The US authorization application was based on data released earlier this month by Merck and Biotherapeutics Ridgeback partners.
Data shows Molnupiravir almost splitting twice the risk of hospitalization or death in patients who are not treated at the hospital with Covid-19 which is light to medium.